NCT05878678 is a Phase 2 clinical trial of Fixed positions of arm down and arm up in Breast Cancer, sponsored by Shanghai Proton and Heavy Ion Center.

Who is sponsoring NCT05878678?

NCT05878678 is sponsored by Shanghai Proton and Heavy Ion Center.

What drugs are being tested in NCT05878678?

Interventions in NCT05878678: Fixed positions of arm down and arm up.

What condition does NCT05878678 study?

NCT05878678 studies Breast Cancer.

Is NCT05878678 still recruiting?

NCT05878678 is currently status unknown. Last updated 26 May 2023.

Last reviewed 2023-05-26 · How we verify

NCT05878678

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective Study of Particle Radiotherapy for Breast Cancer With Different Arm Position

Status unknown Phase 2 Last updated 26 May 2023

What this trial tests

Phase 2 trial testing Fixed positions of arm down and arm up in Breast Cancer in 200 participants. Status unknown.

Timeline

15 May 2023

Primary endpoint
30 May 2024

30 July 2024

Quick facts

Lead sponsor	Shanghai Proton and Heavy Ion Center
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	200
Start date	15 May 2023
Primary completion	30 May 2024
Estimated completion	30 July 2024
Sites	1 location across China

Drugs / interventions tested

Fixed positions of arm down and arm up

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Shanghai Proton and Heavy Ion Center — full company profile →

Who can join

Adults 18 to 80, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The optical body surface image (C-RAD) was used to guide and track the change of positions, and multimodal images (including 2D X-ray images, CT images and PET-CT images) were used to verify the treatment positions. In order to explore the accuracy of breast cancer patients' treatment positions and its impact on dose of the new fixation device in two different fixed positions of arm up and arm down, optimize the position fixed equipment and methods of particle radiotherapy for breast cancer, and then establish the precision process of particle radiotherapy for breast cancer under the guidance of multimodal images. In a word, this is a dosimetry and prospective Phase II randomized clinical study of the accuracy of multi-modal guided particle radiotherapy for postoperative breast cancer with different arm position.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Shanghai Proton and Heavy Ion Center trials

Trials by the same sponsor.

NCT07135661 — Ultra-Hypofractionated vs. Moderately Hypofractionated Proton Therapy for Early Breast Cancer After Lumpectomy · NA · recruiting
NCT05613452 — Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer · Phase 2 · recruiting
NCT06677879 — A Prospective Cohort Study of Proton and Photon Therapy for Left-sided Breast Cancer. · Phase 2 · recruiting
NCT05692661 — A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer · Phase 1 · unknown
NCT05692674 — A Prospective Phase II Study for Adjuvant Hypofractionated Intensity-modulated Proton Radiotherapy for Post Operative Br · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05878678 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Proton and Heavy Ion Center
Last refreshed: 26 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05878678.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing